Neuroprotective Effects of Calpain Inhibition in Parkinson’s Disease: Insights from Cellular and Murine Models
Open Access
Abstract
Parkinson’s disease (PD) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra, and key pathways such as neuroinflammation, oxidative stress, and autophagy are believed to significantly contribute to the mechanisms of neurodegeneration. Calpain activation plays a critical role in neuroinflammation and neurodegeneration, as demonstrated by its impact on microglial activation, reactive oxygen species (ROS) production, and neuronal survival. In this study, we investigated the effects of calpain inhibition using calpeptin (CP) and calpain-2-specific inhibitors in cellular and murine models of neuroinflammation and PD. In BV2 microglial cells, LPS-induced production of pro-inflammatory cytokines (TNF-α, IL-6) and chemokines (MCP-1, IP-10) were significantly reduced by CP treatment with a concomitant decrease in ROS generation. Similarly, in VSC-4.1 motoneuron cells, calpain inhibition attenuated IFN-γ-induced ROS production and improved cell viability, demonstrating its neuroprotective effects. Moreover, in a murine MPTP model of PD, calpain inhibition reduced astrogliosis, ROCK2 expression, and levels of inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-7, and IL12p70) and chemokines (MCP-1 and IP-10) in the dorsal striatum and plasma. The specific role of calpain-2 in immune modulation was further highlighted in human microglia, SV-40 cells. With respect to immune modulation in these cells, siRNA-mediated knockdown of calpain-2, but not calpain-1, significantly reduced antigen presentation to CD4+ T cells. Thus, calpain-2 is likely involved in regulating antigen presentation and activation of inflammatory CD4+ T cells. These findings underscore the therapeutic potential of calpain-2 inhibition in mitigating neuroinflammation and neurodegeneration, particularly in PD, by targeting microglial activation, ROS production, and neuronal survival pathways.Keywords
Funding Information
- Veterans Administration (BX006101, BX001262, SCIRF #2016 I-03, SCIRF #2018 I-01, IK6BX005964, 1R21NS118393-01)
- South Carolina State Spinal Cord Injury Research Fund (BX006101, BX001262, SCIRF #2016 I-03, SCIRF #2018 I-01, IK6BX005964, 1R21NS118393-01)
- Department of Veterans Administration (BX006101, BX001262, SCIRF #2016 I-03, SCIRF #2018 I-01, IK6BX005964, 1R21NS118393-01)
- National Institutes of Health (BX006101, BX001262, SCIRF #2016 I-03, SCIRF #2018 I-01, IK6BX005964, 1R21NS118393-01)
This publication has 79 references indexed in Scilit:
- Calpain‐2 inhibitor treatment preferentially reduces tumor progression for human colon cancer cells expressing highest levels of this enzymeCancer Medicine, 2017
- The IL-1β phenomena in neuroinflammatory diseasesJournal of Neural Transmission, 2017
- Macrophage Inflammatory Protein-1 Alpha (MIP-1 Alpha)/CCL3: As a Biomarker2014
- Protein aggregation in amyotrophic lateral sclerosisActa Neuropathologica, 2013
- A possible cross-talk between autophagy and apoptosis in generating an immune response in melanomaApoptosis, 2012
- Astrocytes: biology and pathologyActa Neuropathologica, 2009
- TNF‐mediated inflammatory diseaseThe Journal of Pathology, 2007
- TNF? and the TNF receptor superfamily: Structure-function relationship(s)Microscopy Research and Technique, 2000
- Cytokine-induced production of macrophage inflammatory protein-1α (MIP-1α) in cultured human astrocytesJournal of Neuroscience Research, 1999
- The role of MIP-1α in Inflammation and hematopoiesisJournal of Leukocyte Biology, 1996